247221-13-2

Upstream product

• 101711-78-8 (3R)-3-propionyl-4-benzyloxazolidin-2-one 
• 247221-12-1 (3R)-3-[(4R)-2,2-diethyl-[1,3]dioxolan-4-yl]-3-(4-methoxybenzyloxy)propanal 
• 247221-11-0 (3R)-3-[(4R)-2,2-diethyl-[1,3]dioxolan-4-yl]-3-(4-methoxybenzyloxy)propan-1-ol 
• 247221-10-9 (3R)-3-[(4R)-2,2-diethyl-[1,3]dioxolan-4-yl]-3-(4-methoxybenzyloxy)propene 
• 135972-13-3 (2S,3S)-2,3-O-(4-methoxybenzylidene)-diethyl tartrate 
• 152386-87-3 (2S)-2-[(4R)-2,2-diethyl-[1,3]dioxolan-4-yl]-2-(4-methoxybenzyloxy)-acetaldehyde 
• 152386-85-1 (1R,2S)-1-((R)-2,2-diethyl-1,3-dioxolan-4-yl)-2-((4-methoxybenzyl)oxy)ethan-1-ol 
• 152386-83-9 [(4R,5R)-5-Hydroxymethyl-2-(4-methoxy-phenyl)-[1,3]dioxolan-4-yl]-methanol 
• 152386-84-0 (2R,3R)-2-O-(4-methoxybenzyl)-1,2,3,4-butanetetrol 

Relevant academic research and scientific papers

An aldol approach to a building block corresponding to the C21-C26-part of FK506

Starting from D-tartrate 2, the chiral aldehyde 10 was prepared in 8 steps. Key steps include the reductive opening of the p-methoxybenzyl acetal 4 and the elongation of the aldehyde 7 via Wittig and hydroboration reaction providing the alcohol 9. Subsequent Evans aldol reaction provided compound 12 which corresponds to the C21-C26 part of the immunosuppressive FK506. Wiley-VCH Verlag GmbH, 1999.